Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients

Homeostatic cytokines in immune reconstitution and graft-versus-host disease

(2016) Stéphanie Thiant et al.   CYTOKINE

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

(2015) Simon-David Gauthier et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

(2015) Y. Chalandon et al.   BLOOD

TCR triggering modulates the responsiveness and homeostatic proliferation of CD4+ thymic emigrants to IL-7 therapy

(2013) O. Hennion-Tscheltzoff et al.   BLOOD

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

(2013) A. Olivieri et al.   BLOOD

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD

(2012) A. de Masson et al.   BLOOD

Imatinib Sensitizes T-cell Lymphocytes From Chronic Myeloid Leukemia Patients to FasL-induced Cell Death

(2012) Laurence Legros et al.   JOURNAL OF IMMUNOTHERAPY

Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse

(2010) S Thiant et al.   BONE MARROW TRANSPLANTATION

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD